NuCana plc (NCNA)
NASDAQ: NCNA · Real-Time Price · USD
2.110
+0.020 (0.96%)
At close: May 8, 2026, 4:00 PM EDT
2.190
+0.080 (3.79%)
After-hours: May 8, 2026, 7:29 PM EDT
NuCana Employees
As of December 31, 2025, NuCana had 12 total employees, including 10 full-time and 2 part-time employees. The number of employees decreased by 10 or -45.45% compared to the previous year.
Employees
12
Change (1Y)
-10
Growth (1Y)
-45.45%
Revenue / Employee
n/a
Profits / Employee
-$3,292,171
Market Cap
8.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 12 | -10 | -45.45% | 10 | 2 |
| Dec 31, 2024 | 22 | -6 | -21.43% | 20 | 2 |
| Dec 31, 2023 | 28 | -3 | -9.68% | 25 | 3 |
| Dec 31, 2022 | 31 | -2 | -6.06% | 28 | 3 |
| Dec 31, 2021 | 33 | 4 | 13.79% | 31 | 2 |
| Jun 30, 2021 | 28 | - | - | 28 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| PMGC Holdings | 34 |
| Bolt Biotherapeutics | 23 |
| CalciMedica | 16 |
| Genprex | 13 |
| XTL Biopharmaceuticals | 10 |
| Can-Fite BioPharma | 5 |
| Creative Medical Technology Holdings | 4 |
NCNA News
- 7 weeks ago - NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - NuCana appoints Bruce as COO - TheFly
- 4 months ago - NuCana Appoints Theresa Bruce as Chief Operating Officer - GlobeNewsWire
- 5 months ago - NuCana presents latest clinical data at ESMO 2025 on NUC-7738 - TheFly
- 5 months ago - NuCana presents data at ESMO on NUC-7738 - TheFly
- 5 months ago - NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma - GlobeNewsWire
- 6 months ago - NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - NuCana announces grant of composition-of-matter patent for NUC-7738 in China - TheFly